JP3032566B2 - External preparation for skin - Google Patents
External preparation for skinInfo
- Publication number
- JP3032566B2 JP3032566B2 JP2295677A JP29567790A JP3032566B2 JP 3032566 B2 JP3032566 B2 JP 3032566B2 JP 2295677 A JP2295677 A JP 2295677A JP 29567790 A JP29567790 A JP 29567790A JP 3032566 B2 JP3032566 B2 JP 3032566B2
- Authority
- JP
- Japan
- Prior art keywords
- skin
- effect
- present
- external preparation
- effective
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Cosmetics (AREA)
Description
【発明の詳細な説明】 ［産業上の利用分野］ 本発明は皮膚外用剤、さらに詳しくは肌荒れを防止、
改善し、また皮膚に対する美白効果に優れ、さらに安全
性の高い皮膚外用剤に関する。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention relates to an external preparation for skin, more specifically, to prevent rough skin,
The present invention relates to an external preparation for skin which is improved, has an excellent whitening effect on the skin, and is highly safe.
［従来の技術］ 皮膚外用剤には種々の薬効成分が配合されている。そ
の中で肌荒れ防止、肌荒れ改善効果および美白効果も薬
効の一つであり、これらを目的とする化粧料等の皮膚外
用剤が求められていた。[Prior Art] Various medicinal ingredients are blended in an external preparation for skin. Among them, the prevention of skin roughness, the effect of improving skin roughness, and the effect of whitening are also one of the medicinal effects, and external preparations such as cosmetics for these purposes have been demanded.
こうした中で従来は、天然物から抽出した各種原料、
たとえばタンパク質、多糖、抽出エキス、天然高分子等
がその使用効果が特徴的であるため皮膚外用剤に配合さ
れてきた。Under these circumstances, conventionally, various raw materials extracted from natural products,
For example, proteins, polysaccharides, extract extracts, natural polymers, and the like have been used in external preparations for skin because of their characteristic use effects.
［発明が解決しようとする課題］ しかしながら、その効果は十分ではなく、より優れた
効果のある薬効剤の開発が待望されていた。[Problems to be Solved by the Invention] However, the effect is not sufficient, and development of a medicinal agent having a more excellent effect has been desired.
本発明は前記従来技術の問題点に鑑みなされたもので
あり、その目的は肌荒れ防止、肌荒れ改善効果により優
れ、さらに美白効果をも併せ持った皮膚外用剤を提供す
ることにある。The present invention has been made in view of the above-mentioned problems of the prior art, and an object of the present invention is to provide an external preparation for skin that is more excellent in the effect of preventing and improving skin roughness and also has a whitening effect.
前記目的を達成するため、本発明者らは安全性に優れ
た物質の中から特に肌荒れを防止し、肌荒れを改善する
効果に優れ、さらに美白効果をも有する物質を得るべく
鋭意研究を重ねた結果、プロテアーゼ阻害剤の一種又は
二種以上と、ケトースの一種又は二種以上とを配合する
ことにより、増殖性の表皮肥厚、紅斑を伴う乾燥、落屑
性の変化に対して極めて有効であり、さらに色素沈着を
も有効に防止、改善することを見出した。In order to achieve the above object, the present inventors have intensively studied to obtain a substance having an excellent effect of preventing skin roughness, improving skin roughness, and also having a whitening effect, among substances having excellent safety. As a result, by combining one or more protease inhibitors and one or more ketoses, proliferative epidermal thickening, dryness with erythema, and extremely effective against changes in desquamation, Furthermore, they have found that pigmentation can be effectively prevented and improved.
本発明者らは上記知見に基づいて本発明を完成するに
至った。The present inventors have completed the present invention based on the above findings.
［課題を解決するための手段］ すなわち、本発明はプロテアーゼ阻害剤から選ばれる
一種または二種以上と、ケトースから選ばれる一種また
は二種以上とを含有することを特徴とする皮膚外用剤で
ある。[Means for Solving the Problems] That is, the present invention is an external preparation for skin characterized by containing one or more selected from protease inhibitors and one or more selected from ketoses. .
以下、本発明の構成について説明する。 Hereinafter, the configuration of the present invention will be described.
プロテアーゼまたは蛋白分解酵素は、ペプチド結合の
加水分解を触媒する酵素を総称した名称である。このプ
ロテアーゼは、ペプチダーゼおよびプロテイナーゼに分
類される。前者は、蛋白質またはペプチド鎖のアミノ基
末端やカルボキシル基末端の外側より、ペプチド結合を
切り離していく酵素で、後者のプロテイナーゼはペプチ
ド鎖の内部の特定の結合を切断する酵素である。また、
このプロテイナーゼは習慣的に広義の『プロテアーゼ』
の名称で呼ばれることが多く、さらにこれらはその活性
部位の性質により、１）セリン系、２）チオール（シス
テイン）系、３）カルボキシル系および４）金属系プロ
テイナーゼの４種類に大別され、それぞれ特異的な阻害
剤が存在している。Protease or proteolytic enzyme is a generic name for enzymes that catalyze the hydrolysis of peptide bonds. This protease is classified into peptidases and proteinases. The former is an enzyme that cleaves peptide bonds from outside the amino or carboxyl terminal of a protein or peptide chain, and the latter is an enzyme that cleaves a specific bond inside a peptide chain. Also,
This proteinase is customarily a "protease"
These are generally classified into four types: 1) serine, 2) thiol (cysteine), 3) carboxyl, and 4) metalloproteinases, depending on the nature of the active site. Specific inhibitors exist.
本発明におけるプロテアーゼ阻害剤とは、前記プロテ
アーゼまたは蛋白分解酵素の加水分解作用を、可逆的も
しくは不可逆的に阻害し得る全ての化学物質を意味す
る。The protease inhibitor in the present invention means any chemical substance capable of reversibly or irreversibly inhibiting the hydrolysis of the protease or proteolytic enzyme.
以下に主な物質を挙げる。 The main substances are listed below.
（１）動物または植物由来の化合物 好ましくはウシ膵塩基性トリプシンインヒビター、ア
プロチニン、ダイズトリプシンインヒビター、リマ豆プ
ロテアーゼインヒビター、トウモロコシプロテアーゼイ
ンヒビター等がある。(1) Animal or plant-derived compounds Preferably, there are bovine pancreatic basic trypsin inhibitor, aprotinin, soybean trypsin inhibitor, lima bean protease inhibitor, corn protease inhibitor and the like.
（２）微生物由来の化合物 好ましくはアンチパイン、プラスミノストレプチン、
さらには下記の一般式で表わされるロイペプチンと総称
される化合物等がある。(2) Microorganism-derived compound Preferably, antipine, plasminostreptin,
Further, there are compounds generally referred to as leupeptin represented by the following general formula.
（３）ベンザミジンおよびその誘導体 好ましくはベンザミジン、ｐ−アミノベンザミジン、
ｍ−アミノベンザミジン、フェニルグアノジン、（2R,4
R）−４−メチル−１−［N2−（３−メチル−1,2,3,4−
テトラヒドロ−８−キノリンスルホニル）−Ｌ−アルギ
ニル］−２−ピペリジンカルボキシリック アシッドモ
ノヒドレート、ダンシルアルギニンＮ−（３−エチル−
1,5−ペンタネジル）アミド等がある。 (3) benzamidine and its derivatives, preferably benzamidine, p-aminobenzamidine,
m-aminobenzamidine, phenylguanosine, (2R, 4
R) -4- methyl -1- [N 2 - (3- methyl-1,2,3,4
Tetrahydro-8-quinolinesulfonyl) -L-arginyl] -2-piperidinecarboxyl acid monohydrate, dansylarginine N- (3-ethyl-
1,5-pentanyl) amide and the like.
（４）アセタミドおよびその誘導体 好ましくはアセタミド、２−フェニルアセタミド、シ
クロヘキシルカイオキサミド等がある。(4) Acetamide and its derivatives Preferably, there are acetamide, 2-phenylacetamide, cyclohexylkaioxamide and the like.
（５）グアニジンおよびその誘導体 好ましくはフェニルグアニジン、シクロヘキシルグア
ニジン等がある。(5) Guanidine and its derivatives Preferably, there are phenylguanidine, cyclohexylguanidine and the like.
（６）ω−アミノ酸類 好ましくはトラネキサム酸、ｐ−アミノメチル安息香
酸、４−アミノメチルビシクロ（2.2.2.）オクタン−１
−カルボン酸、５−［トランス−４（アミノメチル）シ
クロヘキシル］テトラゾール、３−［トランス−４（ア
ミノメチル）シクロヘキシル−２−オキソプロピオネー
ト、トランス−４−（アミノメチル）シクロヘキシル
グリオキサル モノヒドレート、トランス−４−（アミ
ノメチル）シクロヘキサン ヒドロキサミックアシッド
または下記一般式においてｎ＝１〜８の炭素鎖を示す物
質等がある。(6) ω-amino acids preferably tranexamic acid, p-aminomethylbenzoic acid, 4-aminomethylbicyclo (2.2.2.) Octane-1
-Carboxylic acid, 5- [trans-4 (aminomethyl) cyclohexyl] tetrazole, 3- [trans-4 (aminomethyl) cyclohexyl-2-oxopropionate, trans-4- (aminomethyl) cyclohexyl
Glyoxal monohydrate, trans-4- (aminomethyl) cyclohexane hydroxamic acid, a substance having a carbon chain of n = 1 to 8 in the following general formula, and the like are given.
NH2（CH2）nCOOH これらω−アミノ酸の中で、トラネキサム酸およびｐ−
アミノメチル安息香酸に特に優れた効果が認められる。NH 2 (CH 2 ) nCOOH Among these ω-amino acids, tranexamic acid and p-
Aminomethylbenzoic acid is particularly effective.
（７）フルオロリン酸およびその誘導体 好ましくはジイソプロピルフルオロリン酸がある。(7) Fluorophosphoric acid and its derivatives Preferably, there is diisopropylfluorophosphoric acid.
（８）フルオロスルホン酸およびその誘導体 好ましくはフェニルメタンスルホニルフルオリド、
［（ｐ−アミジノフェニル）メタンスルホニルフルオリ
ド等がある。(8) fluorosulfonic acid and its derivatives, preferably phenylmethanesulfonyl fluoride,
[(P-amidinophenyl) methanesulfonyl fluoride and the like.
（９）グアニジノ安息香酸およびその誘導体 好ましくはｐ−ニトロフェニル−ｐ′−グアニジノ安
息香酸、３′,6′−ビス（４−グアニジノベンゾイロキ
シ）−５−（Ｎ′−４−カルボキシフェニル）チオウレ
イドスピロ［イソベンゾフラン−１（3H）,9′−（9H）
キサンゼン］−３−オン等がある。(9) Guanidinobenzoic acid and its derivatives preferably p-nitrophenyl-p'-guanidinobenzoic acid, 3 ', 6'-bis (4-guanidinobenzoyloxy) -5- (N'-4-carboxyphenyl) Thioureido spiro [isobenzofuran-1 (3H), 9 '-(9H)
Xanzen] -3-one.
（10）リジンおよびその誘導体 好ましくは下記一般式で表わされる化合物等がある。(10) Lysine and derivatives thereof Preferably, there are compounds represented by the following general formula.
本発明は、これらに限定されるものではないが、これ
らリジンおよびその誘導体の中でR2＝CH2Clが特に好ま
しい。 Although the present invention is not limited to these, R 2 CHCH 2 Cl is particularly preferred among these lysines and derivatives thereof.
（11）アルギニンおよびその誘導体 好ましくは下記一般式で表わされる化合物等がある。(11) Arginine and derivatives thereof There are preferably compounds represented by the following general formula.
上記アルギニンおよびその誘導体の中でR2＝CH2Clに
特に好ましい。 Among the above arginines and their derivatives, R 2 CHCH 2 Cl is particularly preferred.
本発明に用いられるケトースとしては、エリトルロー
ス、リブロース、キシルロース、プシコース、フルクト
ース、ソルボースおよびタガトース等が挙げられる。Examples of the ketose used in the present invention include erythrulose, ribulose, xylulose, psicose, fructose, sorbose, tagatose and the like.
本発明においては上記プロテアーゼ阻害剤の中から一
種または二種以上と、ケトースの一種または二種以上と
を併用して用いることで肌荒れ防止、改善効果および美
白効果をより向上させることができる。In the present invention, by using one or more of the above protease inhibitors in combination with one or more of ketoses, it is possible to further improve the prevention of skin roughness, the improvement effect, and the whitening effect.
本発明においてプロテアーゼ阻害剤の皮膚外用剤への
配合量は、組成物全量中0.0001〜10重量％が好ましく、
0.001〜５重量％がより好ましい。0.0001重量％未満で
は本発明の効果が十分ではなく、10重量％を超えると製
剤上好ましくなく、かつコスト的にも不利である。また
併用するケトースの配合量は皮膚外用剤全量中0.01〜10
重量％が好ましい。In the present invention, the amount of the protease inhibitor in the external preparation for skin is preferably 0.0001 to 10% by weight based on the total amount of the composition,
0.001 to 5% by weight is more preferred. If it is less than 0.0001% by weight, the effect of the present invention is not sufficient, and if it exceeds 10% by weight, it is not preferable in terms of formulation and it is disadvantageous in terms of cost. The amount of the ketose used in combination is 0.01 to 10 in the total amount of the external preparation for skin.
% By weight is preferred.
本発明の皮膚外用剤は前記の必須成分に加えて、必要
に応じ、本発明の効果を損なわない範囲内で、化粧料、
医薬部外品、医薬品等に一般に用いられる各種成分、水
性成分、保湿剤、増粘剤、紫外線吸収剤、防腐剤、酸化
防止剤、香料、色剤、薬剤、生薬等を配合することがで
きる。The external preparation for skin of the present invention, in addition to the above essential components, if necessary, within a range not impairing the effects of the present invention, cosmetics,
Various components commonly used in quasi-drugs, pharmaceuticals, etc., aqueous components, humectants, thickeners, ultraviolet absorbers, preservatives, antioxidants, fragrances, coloring agents, drugs, crude drugs, etc. can be compounded. .
また、本発明の皮膚外用剤の剤型は任意であり、例え
ば、化粧水等の可溶化系、乳液、クリーム等の乳化系あ
るいは軟膏、粉末分散系、水−油二層系、水−油−粉末
三層系等どのような剤型でもかまわない。The dosage form of the external preparation for skin of the present invention is arbitrary. -Any dosage form such as a three-layer powder system is acceptable.
［実施例］ 次に実施例によって本発明をさらに詳細に説明する。
尚、本発明はこれによって限定されるものではない。[Examples] Next, the present invention will be described in more detail with reference to Examples.
Note that the present invention is not limited to this.
実施例に先立ち、本発明で用いた試験法、評価法を説
明する。Prior to the examples, test methods and evaluation methods used in the present invention will be described.
実使用テスト 本発明に係わる皮膚外用剤の外皮適用による効果を、
肌荒れ、カミソリまけおよび色素沈着に対する改善率か
ら評価した。Actual use test The effect of skin application of the external preparation for skin according to the present invention was
Evaluation was made based on the rate of improvement against rough skin, razor shade and pigmentation.
肌荒れ改善効果 肌荒れあるいは日焼け後の肌のほてりの病状で悩む被
験者各60名で実施し、表−１に示す組成のローションを
顔面に塗布し、２週間後肌状態を目視で判定した。また
カミソリまけする男性被験者60名を対象に髭剃り直後に
表−１に示す組成のローションを塗布し、カミソリまけ
に対する効果を判定した。各判定基準は以下の通りとし
た。Skin roughness improvement effect The test was performed on 60 subjects each suffering from skin roughness or hot flashes after sunburn, lotions having the composition shown in Table 1 were applied to the face, and two weeks later, the skin condition was visually determined. In addition, a lotion having the composition shown in Table 1 was applied to 60 male subjects to be razored immediately after shaving, and the effect on razoring was determined. Each criterion was as follows.
肌荒れに対する改善効果 著効：症状の消失したもの 有効：症状が弱くなったもの やや有効：症状がやや弱くなったもの 無効：症状に変化を認めないもの カミソリまけに対する改善効果 著効：カミソリまけの消失したもの 有効：カミソリまけが非常に改善したもの やや有効：カミソリまけがやや改善したもの 無効：カミソリまけに変化を認めないもの （判定） ◎：被験者が著効、有効およびやや有効を示す割合（有
効率）が80％以上 ○：被験者が著効、有効およびやや有効を示す割合（有
効率）が50％以上〜80％未満 △：被験者が著効、有効およびやや有効を示す割合（有
効率）が30％以上〜50％未満 ×：被験者が著効、有効およびやや有効を示す割合（有
効率）が30％未満 表−２から明らかなようにトラネキサム酸とフルクト
ースとを配合する本発明のローションはブランクローシ
ョンより、肌荒れ、カミソリまけに対して優れた改善効
果を示した。Improvement effect on rough skin Significant effect: Elimination of symptoms Effective: Slightly weakened symptoms Slightly effective: Slightly weakened symptoms Ineffective: No change in symptoms No improvement in razor shade Disappeared Effective: Very improved razor discoloration Slightly effective: Razor discoloration slightly improved Ineffective: No change in razor discoloration observed (Judgment) ◎: Percentage of subjects showing significant, effective and slightly effective (Effective rate) is 80% or more ○: The proportion of the subjects showing significant, effective and somewhat effective (effective rate) is 50% or more and less than 80% △: The proportion of the subjects showing significant, effective and somewhat effective (Yes Efficiency) is 30% or more to less than 50% ×: The proportion (effective rate) at which the subject shows significant, effective and slightly effective (effective rate) is less than 30% As is clear from Table 2, the lotion of the present invention containing tranexamic acid and fructose showed an excellent improvement effect on rough skin and razor spotting compared to the blank lotion.
肌荒れ改善効果試験 実施例１で得たローションと比較例１〜５を用いて人
体パネルで肌荒れ改善効果試験を行なった。即ち、女性
健常人（顔面）の皮膚表面形態をミリスン樹脂によるレ
プリカ法を用いて肌のレプリカを取り、顕微鏡（17倍）
にて観察する。皮紋の状態及び角層の剥離状態から表−
３に示す基準に基づいて肌荒れ評価1,2と判断されたも
の（肌荒れパネル）20名を用い、顔面左右半々に、実施
例１で得たローションと比較例１〜５を１日１回２週間
塗布した。２週間後、再び上述のレプリカ法にて肌の状
態を観察し、表−３の判定基準に従って評価した。Skin roughness improvement effect test A skin roughness improvement effect test was performed on a human body panel using the lotion obtained in Example 1 and Comparative Examples 1 to 5. That is, a replica of the skin is taken from the skin surface morphology of a healthy female person (face) using a replica method with a millisin resin, and a microscope (17 ×)
Observe at Table based on the state of the skin print and the peeled state of the stratum corneum
The lotion obtained in Example 1 and the comparative examples 1 to 5 were applied to the left and right half of the face twice a day using 20 persons (roughness panel) judged to have rough skin evaluations 1 and 2 based on the criteria shown in 3. It was applied for a week. Two weeks later, the skin condition was observed again by the replica method described above, and evaluated according to the criteria shown in Table-3.
表−４から判るように、本発明のローションはブラン
クローションと比較し、顕著な肌荒れ改善効果が認めら
れた。 As can be seen from Table 4, the lotion of the present invention showed a remarkable skin roughness improving effect as compared with the blank lotion.
抗色素沈着効果 ＜薬理効果試験＞ 抗色素沈着効果および副作用 8MOP処理光毒性色素沈着Weiser Maple GPを用いて、
毛刈りした背部に50μのテストサンプルを１日１回約
4cm2の範囲に８週間塗布し、抗色素沈着効果および副作
用としてあらわれた色素増強の程度を表−５に示した４
点評価法（＋の評価点は脱色効果、−の評価点は副作
用）にて表した。使用サンプルはアスコルビン酸水溶液
と、トラネキサム酸とフルクトースの混合水溶液を用い
た。Anti-pigmentation effect <Pharmacological effect test> Anti-pigmentation effect and side effects Using 8MOP-treated phototoxic pigmentation Weiser Maple GP,
50μ test sample on shaved back about once a day
It was applied for 8 weeks in a range of 4 cm 2 , and the degree of pigment enhancement that appeared as an anti-pigmentation effect and side effect was shown in Table 5 below.
It was expressed by a point evaluation method (a positive evaluation point indicates a bleaching effect, and a negative evaluation point indicates a side effect). The samples used were an aqueous solution of ascorbic acid and a mixed aqueous solution of tranexamic acid and fructose.
表−６から明らかなように、アスコルビン酸は長期連
用により、副作用として色素沈着が起こるのに対し、ト
ラネキサム酸とフルクトースの混合水溶液は脱色効果が
優れるとともに、長期連用による副作用を生じなかっ
た。 As is clear from Table-6, ascorbic acid causes pigmentation as a side effect due to long-term use, whereas a mixed aqueous solution of tranexamic acid and fructose has an excellent decolorizing effect and has no side effect due to long-term use.
＜実使用試験＞ 顔面に色素沈着症を有する被験者150名をパネルとし
て、25名には実施例１を、残りの各々25名には比較例１
〜５を１日に２〜３回顔面に使用させ、３カ月連続使用
後、医師により肉眼で淡色化効果の判定を行なった。<Actual use test> 150 subjects having pigmentation on the face were used as panels, and 25 subjects were given Example 1 and the remaining 25 subjects were given Comparative Example 1
5 was used on the face 2-3 times a day, and after 3 consecutive months of use, the doctor evaluated the lightening effect with the naked eye.
＊表中の有効率は、「やや改善」以上が全症例に対して
占める割合である。 * Effective rates in the table are percentages of “slightly improved” or more in all cases.
表−７の結果から明らかなように、トラネキサム酸と
フルクトースを配合した抗色素沈着剤は、雀卵斑、肝
斑、老人性色素斑等、多種の色素沈着症に著しい効果を
有することが示唆された。As is clear from the results in Table 7, it is suggested that the anti-pigmentation agent containing tranexamic acid and fructose has a remarkable effect on various types of pigmentation diseases such as sparrow egg spots, liver spots, and senile pigment spots. Was done.
（製法） 精製水に（１）、（２）、（３）、（７）、（８）を
溶解する。別にエタノールに（５）、（６）、（９）を
溶解し、これを前記の精製水溶液に加えて溶解し、濾過
して化粧水を得た。 (Production method) Dissolve (1), (2), (3), (7) and (8) in purified water. Separately, (5), (6), and (9) were dissolved in ethanol, and this was added to the purified aqueous solution to dissolve and filtered to obtain a lotion.
（１）、（２）、（３）、（４）、（５）、（６）、
（７）、（８）と（９）を加熱溶解し、75℃に保ったも
のを、75℃に加温した（10）（11）と（12）に撹拌しな
がら加える。ホモミキサーで撹拌乳化しながら冷却して
クリームを得た。 (1), (2), (3), (4), (5), (6),
(7), (8) and (9) are heated and dissolved, and those kept at 75 ° C are added to (10), (11) and (12) heated to 75 ° C with stirring. The cream was obtained by cooling while stirring and emulsifying with a homomixer.
（９）に（３）、（４）、（６）、（７）を加え撹拌
溶解する。次に（２）を加え加熱撹拌し、（８）を溶解
した（５）および（１）を加え撹拌溶解してパックを得
た。 (3), (4), (6), and (7) are added to (9), and the mixture is stirred and dissolved. Next, (2) was added, and the mixture was heated and stirred, and (5) and (1), in which (8) was dissolved, were added and dissolved by stirring to obtain a pack.
タルク、顔料をニーダーで十分混合する。（粉末部）
トリエタノールアミンを50％相当量の精製水に加え70℃
に保つ。（水相）香料を除く他の成分を混合し、加熱溶
解して70℃に保つ。（油相）水相に油相を加えホモミキ
サーで均一に乳化し、これを粉末部に加えニーダーで練
り合わせた後、水分を蒸発させ粉砕機で処理する。さら
にこれをよくかきまぜながら香料を均一に噴霧し圧縮成
形する。 Mix talc and pigment well in a kneader. (Powder part)
Add triethanolamine to 50% equivalent of purified water and add 70 ℃
To keep. (Aqueous phase) Other ingredients except fragrance are mixed, dissolved by heating and kept at 70 ° C. (Oil phase) The oil phase is added to the aqueous phase, and the mixture is uniformly emulsified with a homomixer. The mixture is added to a powder portion and kneaded with a kneader. Further, while stirring this well, the fragrance is sprayed uniformly and compression molded.
常法により乳化組成物を作成する。 An emulsion composition is prepared by an ordinary method.
水相、アルコール相を調節後可溶化する。 After adjusting the aqueous phase and alcohol phase, they are solubilized.
実施例２〜７は、肌荒れ防止、改善効果に優れ、また
皮膚に対する美白効果にも優れる安全性の高いものであ
った。Examples 2 to 7 were excellent in the effects of preventing and improving rough skin, and were also highly safe and excellent in the skin whitening effect.
───────────────────────────────────────────────────── フロントページの続き (56)参考文献 特開 平１−93519（ＪＰ，Ａ) 特開 平１−186811（ＪＰ，Ａ) 特開 昭61−115014（ＪＰ，Ａ) 特開 平２−11710（ＪＰ，Ａ) 特開 平２−121917（ＪＰ，Ａ) (58)調査した分野(Int.Cl.7，ＤＢ名) A61K 7/00 ──────────────────────────────────────────────────続 き Continuation of the front page (56) References JP-A-1-93519 (JP, A) JP-A-1-186611 (JP, A) JP-A-61-115014 (JP, A) JP-A-2- 11710 (JP, A) JP-A-2-121917 (JP, A) (58) Fields investigated (Int. Cl. 7 , DB name) A61K 7/00
Claims (1)
は二種以上と、ケトースから選ばれる一種または二種以
上とを含有することを特徴とする皮膚外用剤。1. An external preparation for skin, comprising one or more selected from protease inhibitors and one or more selected from ketoses.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2295677A JP3032566B2 (en) | 1990-11-01 | 1990-11-01 | External preparation for skin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2295677A JP3032566B2 (en) | 1990-11-01 | 1990-11-01 | External preparation for skin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH04169514A JPH04169514A (en) | 1992-06-17 |
| JP3032566B2 true JP3032566B2 (en) | 2000-04-17 |
Family
ID=17823762
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2295677A Expired - Fee Related JP3032566B2 (en) | 1990-11-01 | 1990-11-01 | External preparation for skin |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP3032566B2 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996014085A1 (en) * | 1994-11-08 | 1996-05-17 | Mochida Pharmaceutical Co., Ltd. | External preparation for skin protection |
| US8039026B1 (en) * | 1997-07-28 | 2011-10-18 | Johnson & Johnson Consumer Companies, Inc | Methods for treating skin pigmentation |
| FR2766714B1 (en) * | 1997-08-01 | 2000-01-28 | Gattefosse Ets Sa | ANTI-DEQUAMANT DERMATOLOGICAL COMPOSITION AND METHOD FOR MANUFACTURING SUCH A COMPOSITION |
| ES2273445T3 (en) * | 1997-12-16 | 2007-05-01 | JOHNSON & JOHNSON CONSUMER COMPANIES, INC. | COMPOSITIONS AND PROCEDURES TO REGULATE PHAGOCITOSIS AND EXPRESSION OF ICAM-1. |
| US8093293B2 (en) | 1998-07-06 | 2012-01-10 | Johnson & Johnson Consumer Companies, Inc. | Methods for treating skin conditions |
| US6750229B2 (en) * | 1998-07-06 | 2004-06-15 | Johnson & Johnson Consumer Companies, Inc. | Methods for treating skin pigmentation |
| US8106094B2 (en) | 1998-07-06 | 2012-01-31 | Johnson & Johnson Consumer Companies, Inc. | Compositions and methods for treating skin conditions |
| US8431550B2 (en) | 2000-10-27 | 2013-04-30 | Johnson & Johnson Consumer Companies, Inc. | Topical anti-cancer compositions and methods of use thereof |
| US7192615B2 (en) | 2001-02-28 | 2007-03-20 | J&J Consumer Companies, Inc. | Compositions containing legume products |
| JP6456582B2 (en) * | 2012-09-24 | 2019-01-23 | 共栄化学工業株式会社 | Cosmetic composition |
-
1990
- 1990-11-01 JP JP2295677A patent/JP3032566B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH04169514A (en) | 1992-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH09510969A (en) | Artificial tanning composition having improved stability | |
| JP3032566B2 (en) | External preparation for skin | |
| US20040057974A1 (en) | Antiwrinkle composition and age reversal complex | |
| JPS6268A (en) | Salt of n-acylthiazolysine carboxylic acid and piperidinodiaminopyridine oxide and composition containing the same | |
| EP0678013B1 (en) | Compositions for treatment of the hair | |
| JP2631711B2 (en) | Cosmetics | |
| JP2002541082A (en) | Cosmetic and dermatological skin care compositions | |
| JP2604643B2 (en) | Skin external preparation composition | |
| JP2003531845A (en) | Lipochroman-6 as NO synthase inhibitor and its use | |
| JPS6245527A (en) | Preventive and remedy for gray hair | |
| EP1226822A2 (en) | Promoter for production of nitric oxide or nitric oxide synthase, and cosmetic or pharmaceutical composition comprising the same | |
| JP3936808B2 (en) | How to reduce skin irritation | |
| WO1997037635A1 (en) | External preparations for the amelioration and prevention of chapped skin | |
| JP2957694B2 (en) | Skin external preparation composition | |
| US20040228889A1 (en) | Use of N-arylmethylene ethylenediaminetriacetates, N-arylmethylene iminodiacetated or N,N'-diarylmethylene ethylenediamineacetates as doners of NO | |
| JPH0853337A (en) | Sebum suppressing agent | |
| JPH0680554A (en) | External composition for skin | |
| JPH0853336A (en) | Dermal agent for external use | |
| WO2022113991A1 (en) | Type iii collagen production promoter and antiaging cosmetic | |
| JPH10265365A (en) | External preparation for skin for pimple | |
| Guillot et al. | Anti‐irritant potential of cosmetic raw materials and formulations | |
| EP0087374B1 (en) | Allantoin-hydrolyzed animal protein product | |
| JPH0920643A (en) | External preparation for improving chapped skin | |
| JPS59212417A (en) | External preparation for skin | |
| KR900004088B1 (en) | Cosmetic compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090210 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100210 Year of fee payment: 10 |
|
| LAPS | Cancellation because of no payment of annual fees |